SNSE Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York, NY, on Thursday, December 1, 2022, at 2:00 p.m. ET.

A webcast of Sensei’s presentation will be available in the section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the live webcast is available

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit , and follow the company on Twitter @SenseiBio and .

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

Media Contact:

Chris Railey

Ten Bridge Communications



EN
22/11/2022

Underlying

SNSESensei Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sensei Biotherapeutics

 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockhold...

June 13, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results an...

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate up...

May 6, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizon...

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biot...

April 2, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Up...

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: S...

March 28, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Da...

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors – Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunother...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch